The Baxter and Amgen-backed genome editing technology developer floated in the middle of its range and is now valued at more than $780m.
Precision BioSciences, a US-based genome editing technology developer that counts pharmaceutical companies Amgen and Baxter as investors, raised more than $126m in its initial public offering last week.
The offering consisted of 7.9 million shares issued on the Nasdaq Global Select Market priced at $16.00 each, in the middle of its $15 to $17 range, valuing the company at approximately $784m.
Founded in 2006 and spun out of Duke University, Precision Bio is working on genome editing technology in…
